In 2022, 177Lu-PSMA-617 (Pluvicto®) (Figure 3) was FDA approved for treatment of late stage PCa, showing a reduction ≥50% of PSA levels in PCa patients after their first treatment [39, 40]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.